Inefficiency of cynarin as therapeutic regimen in familial type II hyperlipoproteinaemia.
Seventeen ambulant outpatients with familial Type IIa or Type IIb hyperlipoproteinaemia were treated with Cynarin, the 1,5-dicaffeyl ester of quinic acid, the constituent of the artichoke (Cynara scolymus). The dose tested was 250 mg and 750 mg daily. The mean serum cholesterol and triglyceride concentrations were not significantly changed within 3 months. Cynarin, administered per os, has no hypolipidaemic effect in familial Type II hyperlipoproteinaemia.
D000293:Adolescent; D000328:Adult; D002784:Cholesterol / Q000097:blood; D002934:Cinnamates / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy* / Q000235:genetics*; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood
D002934:Cinnamates; D008074:Lipoproteins; D014280:Triglycerides; D002784:Cholesterol